Education
About Us
Working with TipRanks
Follow Us
Nevro Corp (NVRO)
NYSE:NVRO
NVRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.17 - $14.70
Previous CloseN/A
Volume192.24K
Average Volume (3M)1.39M
Market Cap
$224.48M
Enterprise Value$178.54M
Total Cash (Recent Filing)$94.54M
Total Debt (Recent Filing)$251.16M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Apr 30, 2025EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.05
Shares Outstanding38,372,025
10 Day Avg. Volume1,838,074
30 Day Avg. Volume1,390,103
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.54
Price to Cash Flow (P/CF)2.90
P/FCF Ratio2.90
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.66
Enterprise Value/Ebitda-2.50
Forecast
1Y Price Target
$5.85Price Target Upside0.17% Upside
Rating ConsensusHold
Number of Analyst Covering9
---
Nevro Corp News
---
Bulls Say, Bears Say
Bulls Say
AcquisitionNevro Corp announced an agreement to be acquired by GMED for $5.85/share, which represents a 17% premium to its undisturbed closing price.
Cash GenerationThe company generated $15.5M in cash in Q4, ending with cash and equivalents of $292.5M.
Financial PerformanceQ4 preliminary results ahead of consensus: NVRO announced that it expects Q4/24 revenue in the range of $105M-$106M, ahead of our $98.6M estimate and the Street’s $100.2M.
Bears Say
Market ChallengesThere are ongoing challenges in the spinal cord stimulation market, including increased competitive dynamics and market softness.
Revenue HeadwindsRevenue headwinds expected to persist into 2025 with NVRO citing competition/new product trialing as well as changes to commercial team and optimization of sales territories.
US Trials DeclineUS trials were down -15.2% yr/yr in Q3 after being down -9.5% in Q2 and -5.1% in Q1.
---
Ownership Overview
4.69% Insiders
19.94% Mutual Funds
47.11% Other Institutional Investors
17.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVRO FAQ
What was Nevro Corp’s price range in the past 12 months?
Nevro Corp lowest stock price was $3.17 and its highest was $14.70 in the past 12 months.
What is Nevro Corp’s market cap?
Nevro Corp’s market cap is $224.48M.
When is Nevro Corp’s upcoming earnings report date?
Nevro Corp’s upcoming earnings report date is Apr 30, 2025 which is in 33 days.
How were Nevro Corp’s earnings last quarter?
Nevro Corp released its earnings results on Mar 04, 2025. The company reported -$1.41 earnings per share for the quarter, missing the consensus estimate of -$0.768 by -$0.642.
Is Nevro Corp overvalued?
According to Wall Street analysts Nevro Corp’s price is currently Undervalued.
Does Nevro Corp pay dividends?
Nevro Corp does not currently pay dividends.
What is Nevro Corp’s EPS estimate?
Nevro Corp’s EPS estimate is -0.85.
How many shares outstanding does Nevro Corp have?
Nevro Corp has 38,372,025 shares outstanding.
What happened to Nevro Corp’s price movement after its last earnings report?
Nevro Corp reported an EPS of -$1.41 in its last earnings report, missing expectations of -$0.768. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Nevro Corp?
Currently, no hedge funds are holding shares in NVRO
---
Nevro Corp Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.85 (0.17% Upside)
$5.85 (0.17% Upside)
Blogger Sentiment
Bullish
NVRO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.89%
12-Months-Change
Fundamentals
Return on Equity
-43.28%
Trailing 12-Months
Asset Growth
-12.88%
Trailing 12-Months
Company Description
Nevro Corp
Nevro Corp (NVRO) is a global medical device company that specializes in developing and commercializing innovative solutions for the treatment of chronic pain. The company's flagship product is the Senza spinal cord stimulation (SCS) system, which is designed to deliver high-frequency stimulation to the spinal cord to alleviate pain. Nevro operates primarily within the healthcare and medical device sectors, focusing on improving patient outcomes through advanced technology.
---
NVRO Company Deck
---
NVRO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in cost management, cash position improvement, and new product launches like HFX AdaptivAI, which show promise for future growth. However, the company faced challenges with declining revenue and trial procedures, competitive pressures, and international market issues. While the company is optimistic about its strategic initiatives and new technology, market challenges remain a concern.Read More>---
NVRO Stock 12 Month Forecast
Average Price Target
$5.85
▲(0.17% Upside)
Technical Analysis
Best Analysts Covering NVRO
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+38.38%
reiterated a sell rating 7 months ago
Copying Travis Steed's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +38.38% per trade.
---